Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Activation of Liver X receptors in the heart leads to accumulation of intracellular lipids and attenuation of ischemia-reperfusion injury.

Lei P, Baysa A, Nebb HI, Valen G, Skomedal T, Osnes JB, Yang Z, Haugen F.

Basic Res Cardiol. 2013 Jan;108(1):323. doi: 10.1007/s00395-012-0323-z.

PMID:
23266787
2.

Activation of liver-X-receptor α but not liver-X-receptor β protects against myocardial ischemia/reperfusion injury.

He Q, Pu J, Yuan A, Lau WB, Gao E, Koch WJ, Ma XL, He B.

Circ Heart Fail. 2014 Nov;7(6):1032-41. doi: 10.1161/CIRCHEARTFAILURE.114.001260.

3.

Skeletal muscle as a target of LXR agonist after long-term treatment: focus on lipid homeostasis.

Archer A, Laurencikiene J, Ahmed O, Steffensen KR, Parini P, Gustafsson JÅ, Korach-André M.

Am J Physiol Endocrinol Metab. 2014 Mar 1;306(5):E494-502. doi: 10.1152/ajpendo.00410.2013.

4.

Fasting-induced FGF21 is repressed by LXR activation via recruitment of an HDAC3 corepressor complex in mice.

Archer A, Venteclef N, Mode A, Pedrelli M, Gabbi C, Clément K, Parini P, Gustafsson JÅ, Korach-André M.

Mol Endocrinol. 2012 Dec;26(12):1980-90. doi: 10.1210/me.2012-1151.

PMID:
23073827
5.

Activation of LXRs using the synthetic agonist GW3965 represses the production of pro-inflammatory cytokines by murine mast cells.

Nunomura S, Okayama Y, Matsumoto K, Hashimoto N, Endo-Umeda K, Terui T, Makishima M, Ra C.

Allergol Int. 2015 Sep;64 Suppl:S11-7. doi: 10.1016/j.alit.2015.03.001.

6.

Both liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity.

Korach-André M, Archer A, Barros RP, Parini P, Gustafsson JÅ.

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):403-8. doi: 10.1073/pnas.1017884108.

7.

The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions.

Laffitte BA, Joseph SB, Chen M, Castrillo A, Repa J, Wilpitz D, Mangelsdorf D, Tontonoz P.

Mol Cell Biol. 2003 Mar;23(6):2182-91.

8.

Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRα.

Kiss E, Popovic Z, Bedke J, Wang S, Bonrouhi M, Gretz N, Stettner P, Teupser D, Thiery J, Porubsky S, Adams J, Gröne HJ.

Am J Pathol. 2011 Jul;179(1):92-103. doi: 10.1016/j.ajpath.2011.03.019.

9.

Liver X receptor activation inhibits osteoclastogenesis by suppressing NF-κB activity and c-Fos induction and prevents inflammatory bone loss in mice.

Kim HJ, Yoon KA, Yoon HJ, Hong JM, Lee MJ, Lee IK, Kim SY.

J Leukoc Biol. 2013 Jul;94(1):99-107. doi: 10.1189/jlb.1112601.

10.

Liver X receptor agonist GW3965 dose-dependently regulates lps-mediated liver injury and modulates posttranscriptional TNF-alpha production and p38 mitogen-activated protein kinase activation in liver macrophages.

Wang YY, Dahle MK, Steffensen KR, Reinholt FP, Collins JL, Thiemermann C, Aasen AO, Gustafsson JA, Wang JE.

Shock. 2009 Nov;32(5):548-53. doi: 10.1097/SHK.0b013e3181a47f85.

PMID:
19295476
11.

Simultaneous activation of the liver X receptors (LXRα and LXRβ) drives murine collagen-induced arthritis disease pathology.

Asquith DL, Miller AM, Reilly J, Kerr S, Welsh P, Sattar N, McInnes IB.

Ann Rheum Dis. 2011 Dec;70(12):2225-8. doi: 10.1136/ard.2011.152652.

PMID:
21859686
12.

Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells.

Tsui KH, Chung LC, Feng TH, Lee TY, Chang PL, Chen WT, Juang HH.

Prostate. 2015 May;75(6):603-15. doi: 10.1002/pros.22944.

PMID:
25560459
13.

GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats.

Leik CE, Carson NL, Hennan JK, Basso MD, Liu QY, Crandall DL, Nambi P.

Br J Pharmacol. 2007 Jun;151(4):450-6.

14.

Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke.

Morales JR, Ballesteros I, Deniz JM, Hurtado O, Vivancos J, Nombela F, Lizasoain I, Castrillo A, Moro MA.

Circulation. 2008 Sep 30;118(14):1450-9. doi: 10.1161/CIRCULATIONAHA.108.782300.

15.

Liver X receptor agonist treatment attenuates cardiac dysfunction in type 2 diabetic db/db mice.

He Q, Pu J, Yuan A, Yao T, Ying X, Zhao Y, Xu L, Tong H, He B.

Cardiovasc Diabetol. 2014 Nov 22;13:149. doi: 10.1186/s12933-014-0149-0.

16.

Lipid droplet accumulation is associated with an increase in hyperglycemia-induced renal damage: prevention by liver X receptors.

Kiss E, Kränzlin B, Wagenblaβ K, Bonrouhi M, Thiery J, Gröne E, Nordström V, Teupser D, Gretz N, Malle E, Gröne HJ.

Am J Pathol. 2013 Mar;182(3):727-41. doi: 10.1016/j.ajpath.2012.11.033.

PMID:
23318573
17.

The liver X receptor agonist GW3965 improves recovery from mild repetitive traumatic brain injury in mice partly through apolipoprotein E.

Namjoshi DR, Martin G, Donkin J, Wilkinson A, Stukas S, Fan J, Carr M, Tabarestani S, Wuerth K, Hancock RE, Wellington CL.

PLoS One. 2013;8(1):e53529. doi: 10.1371/journal.pone.0053529.

18.

Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.

van der Hoorn J, Lindén D, Lindahl U, Bekkers M, Voskuilen M, Nilsson R, Oscarsson J, Lindstedt E, Princen H.

Br J Pharmacol. 2011 Apr;162(7):1553-63. doi: 10.1111/j.1476-5381.2010.01168.x.

20.

Activation of liver X receptor attenuates endothelin-1 expression in vascular endothelial cells.

Gao M, Zeng Y, Guan Y, Hu Z, Zhong D, Shen X, Zhang L, Xu Z, Gong W, Zhang Y, Zhang M, Zheng Y, He F.

Int J Biochem Cell Biol. 2012 Dec;44(12):2299-307. doi: 10.1016/j.biocel.2012.09.010.

PMID:
23018104
Items per page

Supplemental Content

Support Center